Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells
about
DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptorThe cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activityActivation of Smad transcriptional activity by protein inhibitor of activated STAT3 (PIAS3)Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancerRegulation of transforming growth factor-beta signaling by protein inhibitor of activated STAT, PIASy through Smad3A new role for the STAT3 inhibitor, PIAS3: a repressor of microphthalmia transcription factorPIAS3 induces SUMO-1 modification and transcriptional repression of IRF-1PIAS1 and PIASxalpha function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcriptionPIAS3 (protein inhibitor of activated STAT-3) modulates the transcriptional activation mediated by the nuclear receptor coactivator TIF2Signal transducer and activator of transcription 5A/B in prostate and breast cancersRole played by microphthalmia transcription factor phosphorylation and its Zip domain in its transcriptional inhibition by PIAS3Interactions between PIAS proteins and SOX9 result in an increase in the cellular concentrations of SOX9.The Role of the Small Ubiquitin-Related Modifier (SUMO) Pathway in Prostate Cancer.Identification of a structural motif in the tumor-suppressive protein GRIM-19 required for its antitumor activityCytokine-induced tumor suppressors: a GRIM storyInterleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes.Transcription factor Stat5a/b as a therapeutic target protein for prostate cancer.PIAS3, an inhibitor of STAT3, has intensively negative association with the survival of gastric cancer.The androgen receptor: structure, mutations, and antiandrogens.STAT3: a potential therapeutic target in dendritic cells for the induction of transplant tolerance.MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis.Tumor-derived mutations in the gene associated with retinoid interferon-induced mortality (GRIM-19) disrupt its anti-signal transducer and activator of transcription 3 (STAT3) activity and promote oncogenesis.Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation.Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer.Egr1 promotes growth and survival of prostate cancer cells. Identification of novel Egr1 target genes.Activation of Stat3 by cell confluence reveals negative regulation of Stat3 by cdk2.Pias3-dependent SUMOylation directs rod photoreceptor development.Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals.The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies
P2860
Q24291490-5B6224BE-B054-486C-9438-C82052CB996DQ24309232-195994C2-14E1-4BA1-932A-04F5B2AFC1D3Q24531180-5D74F5CE-6636-4362-A067-0073427D8171Q24630482-8B6772ED-792D-433B-BC42-6C20115A3021Q28114915-3C624EFE-FF2A-429E-A07B-4F9E5503A913Q28180197-D53CFD7A-8A91-4817-BF53-02203734EA61Q28205504-F4A108B1-83B6-4BC1-8B42-EE164F57A75DQ28208433-7C10A64F-1F0A-4481-9E1D-1898E786A5DCQ28217862-24083DD5-E1E7-4C8B-B140-D5048D8A3EB7Q28220245-719A0F11-3357-4A79-B0BA-B4B57F826A2AQ28281791-D6DDE149-9FD6-4154-9BBB-539992310992Q33195466-B4D98FBD-7C24-464E-91EA-CCD08C93DC83Q33237313-D0DC59F6-F258-4168-A6BD-A9E6C4884A28Q33649507-BBAAA39D-B70B-4249-A00F-1FB8B02EBE27Q34033341-B44EC722-379A-4DF9-9547-269D0D0CBC1BQ34077445-35527C93-2DC8-45E8-B5E4-8EEAAFE4F1B0Q34440657-F511EB54-65DC-4E40-89FB-C9BF1D1542B9Q35012937-DBCC9029-D59B-4349-861E-C8566D6119B2Q35173571-FD1586CC-9889-47A4-B49E-6628694566C8Q35193278-B09AD261-AA00-46A8-B43A-8A77D51C9A5BQ36481079-71B758B6-FCF6-4390-8A7C-3C84E02F46FBQ36671852-D4152479-1259-4FE1-A9E2-C726833E040DQ36685267-125D6404-F300-48E2-9477-4A84273B7B0FQ37148218-58B5A3A0-C09D-4A52-A424-D5C67E54FBE1Q37236912-2808D684-4CB2-4E28-BA20-49D002AD1752Q37393014-BF02346F-F0F4-49A8-BA5C-A4FF44BA8067Q38358220-A2A52727-4188-45CB-8522-26AD3217A18DQ42801009-AA4A193B-B35B-4683-B0E0-D58F3D52CA29Q43106810-3E10DDE6-73A4-45F7-B327-F0B1F20FB17FQ47161820-AF04673E-FA0A-4582-A1F3-237F6E61DD6FQ58742654-3F9F8D7A-268C-4062-8336-3C55623EC46A
P2860
Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Protein inhibitor of activated ...... ng in prostate carcinoma cells
@ast
Protein inhibitor of activated ...... ng in prostate carcinoma cells
@en
Protein inhibitor of activated ...... ng in prostate carcinoma cells
@nl
type
label
Protein inhibitor of activated ...... ng in prostate carcinoma cells
@ast
Protein inhibitor of activated ...... ng in prostate carcinoma cells
@en
Protein inhibitor of activated ...... ng in prostate carcinoma cells
@nl
prefLabel
Protein inhibitor of activated ...... ng in prostate carcinoma cells
@ast
Protein inhibitor of activated ...... ng in prostate carcinoma cells
@en
Protein inhibitor of activated ...... ng in prostate carcinoma cells
@nl
P2093
P356
P1476
Protein inhibitor of activated ...... ng in prostate carcinoma cells
@en
P2093
A Muraguchi
F Saatcioglu
T Yamamoto
P356
10.1006/BBRC.2000.3753
P407
P577
2000-11-11T00:00:00Z